

Product portfolio and pipeline

Approved	Serplulimab ⁽¹⁾ PD-1 sqNSCLC, ES-SCLC, ESCC, nsqNSCLC, GC	HLX01 ⁽²⁾ (rituximab) CD20 NHL, CLL, RA ⁽³⁾	HLX02 ⁽⁴⁾ (trastuzumab) HER2 BC, mGC	HLX03 ⁽⁵⁾ (adalimumab) TNF-α RA, AS, Ps, UV, pJIA, pediatric Ps, CD, pediatric CD
	HLX04 (bevacizumab) ⁽⁶⁾ VEGF mCRC, NSCLC, GBM, HCC, EOC, FTC or PPC, CC	BILDYOS ⁽⁷⁾ (denosumab) RANKL Osteoporosis, etc.	BILPREVDA ⁽⁷⁾ (denosumab) RANKL Cancer-related bone disease, etc.	POHERDY ⁽⁸⁾ (pertuzumab) HER2 BC
Marketing Applications	HLX901 ⁽⁹⁾ (neratinib) HER1/HER2/HER4 BC	Fovinacilib ⁽⁹⁾ CDK4/6 BC		
	HLX04-O ⁽¹⁰⁾ VEGF Wet AMD	HLX14 ⁽⁷⁾ (denosumab) RANKL Osteoporosis, Cancer-related bone disease, etc.	HLX04 (bevacizumab) ⁽⁶⁾ VEGF mCRC, NSCLC, GBM, HCC, CC, EOC, etc.	HLX903 ⁽¹¹⁾ EGFR-TKI NSCLC 1L
Phase 3	Serplulimab ⁽¹⁾ + Chemo PD-1 ES-SCLC 1L	Serplulimab ⁽¹⁾ + Chemo + Radio PD-1 LS-SCLC 1L	Serplulimab ⁽¹⁾ + bevacizumab + Chemo PD-1+VEGF mCRC 1L	HLX04-O ⁽¹⁰⁾ VEGF Wet AMD
	HLX22 ⁽¹²⁾ (dulpatatug) + trastuzumab + Chemo HER2+HER2 GC	HLX87 ⁽¹³⁾ HER2 ADC BC	HLX78 ⁽¹⁴⁾ (lasofofifene) SERM BC	
Phase 2	Serplulimab ⁽¹⁾ + HLX07 ⁽¹⁵⁾ (pimurutamab) PD-1+EGFR Solid tumors (sqNSCLC, etc.)	HLX07 ⁽¹⁵⁾ (pimurutamab) EGFR Solid tumors (cSCC, etc.)	HLX22 ⁽¹²⁾ (dulpatatug) + T-DXd HER2 HER2-low/HR+ BC	HLX43 ⁽¹⁶⁾ PD-L1 ADC Solid tumors (NSCLC, etc.)
	HLX43 ⁽¹⁶⁾ + Serplulimab ⁽¹⁾ PD-L1 ADC + PD-1 Solid tumors	HLX87 ⁽¹³⁾ + HLX22 ⁽¹²⁾ (dulpatatug) HER2 ADC + HER2 BC 1L	HLX79 ⁽¹⁷⁾ + HLX01 (rituximab) ⁽²⁾ Sialidase Fc Fusion Protein + CD20 Active Glomerular Diseases	HLX208 ⁽¹⁷⁾ BRAF V600E Solid tumors
Phase 1	HLX6018 GARP/TGF-β1 IPF	HLX701 ⁽¹⁸⁾ CD47-SIRPα Blockade RAS/BRAF wild-type mCRC	HLX316 B7H3 x Sialidase Solid tumors	HLX37 PD-L1 x VEGF BsAb Solid tumors
	HLX3902 STEAP1 x CD3 x CD28 TsAb PCa	HLX48 c-MET x EGFR BsADC NSCLC, CRC	HLX97 KAT6A/B ERα + Breast Cancer	HLX15 ⁽¹⁹⁾ (daratumumab) CD38 Multiple myeloma
IND/Pre-IND	HLX17 (pembrolizumab) PD-1 NSCLC, TNBC, etc.	HLX319 (pertuzumab + trastuzumab, SC) HER2+HER2 BC	HLX05-N ⁽²⁰⁾ (cetuximab) EGFR mCRC, HNSCC	HLX18 ⁽¹⁵⁾ (nivolumab) PD-1 Solid tumors (NSCLC, MEL, etc.)
	HLX109 IL-1R3 Autoimmune diseases (AD, Psoriasis, etc.)	HLX105 PD1 x IL2v Solid tumors	HLX203 ActRIIA/B lean mass management	HLX68 TL1A x IL23(p19) BsAb IBD (UC, CD, etc.)
	HLX49 HER2 x HER2 ADC Solid tumors (HER2+ BC/GC, etc.)	HLX403 CDH17 ADC Gastrointestinal cancers	HLX41 LIV-1 ADC BC	HLX320 TSHR x IGF1R BsAb TED

■ Innovative mAb
 ■ Innovative fusion protein
 ■ Innovative multi-specific antibody
 ■ Innovative ADC
 ■ Small molecule
 ■ Biosimilar mAb

★ Bridging study in U.S.
 ★ BLA under FDA review
 ★ Global MRCT
 ★ Approved in global markets

- (1) Approved in 50 countries and regions, including China, the UK, Germany, India, Singapore, trade name: Hetronify® in Europe. Business partners: KGbio/ Fosun Pharma/ Intas/ Lotus/ Abbott/ Eisai.
- (2) Approved in China and multiple Latin American countries. The first biosimilar approved in China. Business partners: Fosun Pharma/ Eurofarma/ Abbott/ Boston Oncology.
- (3) The first rituximab approved for the indication in China.
- (4) Approved in 50+ countries, including China, U.S., the UK, Germany, France and Australia, trade name in U.S.: HERCESS™. Trade name in Europe: Zercepac®. Business partners: Accord/ Elea/ Eurofarma/ Abbott/ KGbio/ Getz Pharma.
- (5) Business partners: Fosun Wanbang/ Getz Pharma.
- (6) Approved in China and multiple Latin American countries. Business partners: Eurofarma.
- (7) Approved in North America and Europe. Business partner: Organon. Trade name: BILDYOS® (60mg/mL), BILPREVDA® (120mg/1.7mL) in the U.S. and Europe. Marketing applications are under review in China.
- (8) Approved in China, the U.S. and Europe. Trade name: POHERDY® in the U.S. and Europe. Business partner: Organon.
- (9) Commercialization in China.
- (10) NDA under review in China. Business partner: Essex.
- (11) Exclusive commercialisation rights and development rights in Chinese Mainland and Macau
- (12) IND approvals obtained in China/ the U.S./ Japan/ the EU
- (13) The development and exclusive commercialization rights obtained in China and select ex-China markets.
- (14) Exclusive license obtained in China. Phase 3 MRCT enrolling globally. IND approval obtained in China.
- (15) IND approvals obtained in China/the U.S.
- (16) IND approvals obtained in China/ the U.S./ Japan/ Australia/ Europe.
- (17) Exclusive license obtained in China.
- (18) Exclusive rights in China (excl. Taiwan), several countries in Southeast Asia, and other selected countries and regions; Phase 1b/2a conducting in countries such as China and the U.S.
- (19) IND approvals obtained in China/the U.S. Business partner: Dr. Reddy's, etc.
- (20) Business partner: Sandoz, etc.